Edition:
United States

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

6.96USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$6.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,457
52-wk High
$11.91
52-wk Low
$5.64

Latest Key Developments (Source: Significant Developments)

Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218
Wednesday, 10 Jan 2018 07:30am EST 

Jan 10 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY.  Full Article

Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Friday, 29 Dec 2017 07:30am EST 

Dec 29 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS ISSUES 2018 CORPORATE OUTLOOK.REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35.SEES FY 2018 REVENUE $110 MILLION TO $130 MILLION.SEES FY 2017 REVENUE $165 MILLION TO $175 MILLION.- ‍NDA FILING FOR FT218 EXPECTED BY YEAR-END 2018​.- COMMERCIAL LAUNCH FOR NOCTIVA ON TARGET FOR Q2 2018.FY2017 EARNINGS PER SHARE VIEW $1.48, REVENUE VIEW $171.8 MILLION -- THOMSON REUTERS I/B/E/S.AVADEL PHARMACEUTICALS- AV001 IS EXPECTED TO COMPETE IN AN ESTIMATED MARKET SIZE OF ABOUT $30 - $40 MILLION PER YEAR ONCE LAUNCHED IN 2019.- EXPECTS NEGATIVE CASH FLOW IN 2018.- ‍ASSESSING TAX CUTS AND JOBS ACT OF 2017 AND, ACCORDINGLY, IS UNABLE TO PROVIDE 2018 ADJUSTED DILUTED EPS GUIDANCE​.AVADEL PHARMACEUTICALS - ESTIMATES THAT PEAK REVENUES FOR NOCTIVA COULD BE AS HIGH AS $750 MILLION OR MORE PER YEAR.  Full Article

Flamel technologies announces shareholder approval of cross-border merger
Friday, 12 Aug 2016 07:30am EDT 

Flamel Technologies Sa : Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc . Flamel technologies announces shareholder approval of cross-border merger . Received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger .Under terms of reincorporation, Flamel will merge with and into its wholly owned subsidiary, Avadel Pharmaceuticals Ltd.  Full Article

Flamel Technologies reports Q2 GAAP loss per share $0.48
Monday, 8 Aug 2016 06:05am EDT 

Flamel Technologies SA : Total revenue for Q2 2016 was $38.9 million, compared to $48.6 million during same period last year . Q2 adjusted loss per share $0.02 . Q2 GAAP loss per share $0.48 . Has lowered its 2016 research and development spending guidance to range or $30 to $40 million .2016 revenue guidance increased to $125 to $140 million.  Full Article